Compare AANJANEYA LIFECARE with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. DATSONS LABS vs CIPLA - Comparison Results

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. DATSONS LABS CIPLA DR. DATSONS LABS/
CIPLA
 
P/E (TTM) x -10.9 32.7 - View Chart
P/BV x 0.2 4.6 3.5% View Chart
Dividend Yield % 0.0 0.4 -  

Financials

 DR. DATSONS LABS   CIPLA
EQUITY SHARE DATA
    DR. DATSONS LABS
Mar-14
CIPLA
Mar-20
DR. DATSONS LABS/
CIPLA
5-Yr Chart
Click to enlarge
High Rs126586 21.5%   
Low Rs31357 8.7%   
Sales per share (Unadj.) Rs133.0207.0 64.2%  
Earnings per share (Unadj.) Rs0.218.6 0.8%  
Cash flow per share (Unadj.) Rs6.633.2 19.9%  
Dividends per share (Unadj.) Rs04.00 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs128.8195.5 65.9%  
Shares outstanding (eoy) m31.66806.35 3.9%   
Bonus/Rights/Conversions FCCBESOS-  
Price / Sales ratio x0.62.3 25.9%   
Avg P/E ratio x516.125.3 2,037.2%  
P/CF ratio (eoy) x11.814.2 83.4%  
Price / Book Value ratio x0.62.4 25.2%  
Dividend payout %021.5 0.0%   
Avg Mkt Cap Rs m2,477379,912 0.7%   
No. of employees `000NA25.8 0.0%   
Total wages/salary Rs m5630,270 0.2%   
Avg. sales/employee Rs ThNM6,459.6-  
Avg. wages/employee Rs ThNM1,171.2-  
Avg. net profit/employee Rs ThNM580.2-  
INCOME DATA
Net Sales Rs m4,211166,949 2.5%  
Other income Rs m793,442 2.3%   
Total revenues Rs m4,289170,391 2.5%   
Gross profit Rs m56932,060 1.8%  
Depreciation Rs m20411,747 1.7%   
Interest Rs m4301,974 21.8%   
Profit before tax Rs m1321,782 0.1%   
Minority Interest Rs m0-475 0.0%   
Prior Period Items Rs m-20-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m66,312 0.1%   
Profit after tax Rs m514,995 0.0%  
Gross profit margin %13.519.2 70.3%  
Effective tax rate %48.029.0 165.7%   
Net profit margin %0.19.0 1.3%  
BALANCE SHEET DATA
Current assets Rs m6,852117,038 5.9%   
Current liabilities Rs m6,71143,931 15.3%   
Net working cap to sales %3.343.8 7.6%  
Current ratio x1.02.7 38.3%  
Inventory Days Days16196 168.0%  
Debtors Days Days31885 374.3%  
Net fixed assets Rs m3,673107,424 3.4%   
Share capital Rs m3171,613 19.6%   
"Free" reserves Rs m3,761156,018 2.4%   
Net worth Rs m4,078157,630 2.6%   
Long term debt Rs m1,67123,693 7.1%   
Total assets Rs m12,633236,626 5.3%  
Interest coverage x1.012.0 8.6%   
Debt to equity ratio x0.40.2 272.6%  
Sales to assets ratio x0.30.7 47.2%   
Return on assets %3.47.2 48.0%  
Return on equity %0.19.5 1.2%  
Return on capital %7.712.8 59.8%  
Exports to sales %22.933.0 69.3%   
Imports to sales %14.30-   
Exports (fob) Rs m96455,175 1.7%   
Imports (cif) Rs m602NA-   
Fx inflow Rs m96456,036 1.7%   
Fx outflow Rs m6076,764 9.0%   
Net fx Rs m35749,272 0.7%   
CASH FLOW
From Operations Rs m1,34530,685 4.4%  
From Investments Rs m-2,2561,040 -216.8%  
From Financial Activity Rs m-1,200-29,488 4.1%  
Net Cashflow Rs m-2,1112,340 -90.2%  

Share Holding

Indian Promoters % 4.5 16.0 28.3%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 0.0 12.2 -  
FIIs % 1.4 23.7 5.7%  
ADR/GDR % 0.0 1.1 -  
Free float % 94.1 26.2 359.2%  
Shareholders   20,807 161,166 12.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. DATSONS LABS With:   ALKEM LABORATORIES  STRIDES PHARMA SCIENCE  FDC  TORRENT PHARMA  DISHMAN PHARMA  

Compare DR. DATSONS LABS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

SGX Nifty Down 118 Points, India Top US Crude Oil Buyer in Q1CY21, Adani Ports Removed from S&P Index, and Buzzing Stocks Today(Pre-Open)

Indian share markets ended on a strong note on Tuesday. Benchmark indices extended gains after the Indian government fast-tracked emergency approvals for foreign produced Covid-19 vaccines.

Related Views on News

CIPLA Announces Quarterly Results (3QFY21); Net Profit Up 112.8% (Quarterly Result Update)

Feb 1, 2021 | Updated on Feb 1, 2021

For the quarter ended December 2020, CIPLA has posted a net profit of Rs 8 bn (up 112.8% YoY). Sales on the other hand came in at Rs 52 bn (up 18.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA 2019-20 Annual Report Analysis (Annual Result Update)

Nov 4, 2020 | Updated on Nov 4, 2020

Here's an analysis of the annual report of CIPLA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

Nazara Technologies IPO: Should You Apply? (IPO)

Mar 17, 2021

Should you bet on this gaming company backed by ace investor Rakesh Jhunjhunwala?

CIPLA Announces Quarterly Results (1QFY21); Net Profit Up 21.4% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, CIPLA has posted a net profit of Rs 6 bn (up 21.4% YoY). Sales on the other hand came in at Rs 43 bn (up 7.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (4QFY20); Net Profit Down 35.1% (Quarterly Result Update)

May 19, 2020 | Updated on May 19, 2020

For the quarter ended March 2020, CIPLA has posted a net profit of Rs 2 bn (down 35.1% YoY). Sales on the other hand came in at Rs 44 bn (down 0.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave(Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

An India Revival Stock I'm Bullish On...(Profit Hunter)

Apr 9, 2021

This could take India to the position of 3rd largest economy.

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

Why the Market Fell Yesterday(Fast Profits Daily)

Apr 6, 2021

In this video, I'll tell you the two reasons why the market fell on Monday and how you can prepare yourself for such events in the future.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DR. DATSONS LABS SHARE PRICE


May 21, 2015 (Close)

TRACK DR. DATSONS LABS

  • Track your investment in DR. DATSONS LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DR. DATSONS LABS

DR. DATSONS LABS - GSK PHARMA COMPARISON

COMPARE DR. DATSONS LABS WITH

MARKET STATS